Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04761783 · ClinicalTrials.gov registry record
BESPOKE Study of ctDNA Guided Immunotherapy
A clinical trial, sponsored by Natera.
- Completed
- Registry status
- 290
- Enrollment target
NCT04761783: Completed study, sponsored by Natera.
NCT04761783 is a clinical trial that has completed, run by Natera. The registered enrollment target is 290 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04761783 has completed, sponsored by Natera.
- COMPLETED
- Registry status
- 290 participants
- Enrollment target
Study Summary
This is a prospective data collection study of patients with advanced solid tumors who will receive standard of care immunotherapy (IO) and will be monitored with SIGNATERA™ testing. SIGNATERA™ test will be performed at baseline and during routine care. The test results will be part of assessing tumor response. The correlation between SIGNATERA™ test results and subsequent treatment decisions will be examined to compare actual treatment delivered against treatment decisions potentially impacted by SIGNATERA™ results. Treatment administered, tumor assessment results, time to progression, overall survival, physician questionnaires, and patient-reported outcomes will be collected/recorded.
Primary Outcome
Percent of patients who have their immunotherapy treatment regimen changed due to post-treatment SIGNATERA ctDNA test result
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 290 participants |
| Start Date | 2021-05-28 |
| Est. Completion | 2024-03-30 |
What the finished NCT04761783 record still lists
NCT04761783 is an observational study that tracks outcomes without assigning an intervention. The registered 290 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT04761783 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04761783 about?
NCT04761783 is a clinical study titled "BESPOKE Study of ctDNA Guided Immunotherapy". This is a prospective data collection study of patients with advanced solid tumors who will receive standard of care immunotherapy (IO) and will be monitored with SIGNATERA™ testing. SIGNATERA™ test will be performed at baseline and during routine care. The test results will be part of assessing tum...
What is the current status of trial NCT04761783?
This trial is currently completed. The enrollment target is 290 participants. The study started on 2021-05-28. Estimated completion is 2024-03-30.
Who is sponsoring clinical trial NCT04761783?
This trial is sponsored by Natera, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00775476 · 290 participants · Phase 2
Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine
- NCT01874197 · 290 participants · NA
Branched Thoracic Endovascular Grafts for the Treatment of Thoraco-abdominal Aortic
- NCT04331353 · 290 participants · NA
The Allergen Reduction and Child Health Study (ARCHS)
- NCT04649008 · 290 participants · Early Phase 1
Localizing Epileptic Networks Using MRI and iEEG
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI